A Virtual Reality Orientation and Mobility Test for Inherited Retinal Degenerations: Testing a Proof-of-Concept After Gene Therapy

References

• Bennett CR, Bex PJ, Bauer CM, Merabet LB. The assessment of visual function and functional vision. Semin Pediatr Neurol. 2019;31:30–40. doi:10.1016/j.spen.2019.05.006
   PubMed Web of Science ®Google Scholar
• Shingledecker CA, Foulke E. A human factors approach to the assessment of the mobility of blind pedestrians. Hum Factors. 1978;20(3):273–286. doi:10.1177/001872087802000303
   PubMed Web of Science ®Google Scholar
• Marron JA, Bailey IL. Visual factors and orientation-mobility performance. Am J Optom Physiol Opt. 1982;59(5):413–426. doi:10.1097/00006324-198205000-00009
   PubMedGoogle Scholar
• Chang KJ, Dillon LL, Deverell L, Boon MY, Keay L. Orientation and mobility outcome measures. Clin Exp Optom. 2020;103(4):434–448. doi:10.1111/cxo.13004
   PubMed Web of Science ®Google Scholar
• Maguire AM, Bennett, J, Aleman E, et al. Clinical Perspective: Treating RPE65-Associated Retinal Dystrophy. Mol Ther. 2021;29(2):442–463. doi:10.1016/j.ymthe.2020.11.029.
   Google Scholar
• Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet. 2017;390(10097):849–860. doi:10.1016/S0140-6736(17)31868-8
   PubMed Web of Science ®Google Scholar
• Bainbridge JW, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358(21):2231–2239. doi:10.1056/NEJMoa0802268
   PubMed Web of Science ®Google Scholar
• Jacobson SG, Cideciyan AV, Ratnakaram R, et al. Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in 15 children and adults followed up to 3 years. Arch Ophthalmol. 2012;130(1):9–24. doi:10.1001/archophthalmol.2011.298
   PubMed Web of Science ®Google Scholar
• Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber’s congenital amaurosis. N Engl J Med. 2015;372(20):1887–1897. doi:10.1056/NEJMoa1414221
   PubMed Web of Science ®Google Scholar
• Shapiro A, Corcoran P, Sundstrom C, et al. Development and validation of a portable visual navigation challenge for assessment of retinal disease in multi-centered clinical trials. Invest Ophthalmol Vis Sci. 2017;58(8).
   Web of Science ®Google Scholar
• Jacobson SG, Cideciyan AV, Sumaroka A, et al. Outcome measures for clinical trials of leber congenital amaurosis caused by the intronic mutation in the CEP290 gene. Invest Ophthalmol Vis Sci. 2017;58(5):2609. doi:10.1167/iovs.17-21560
   PubMed Web of Science ®Google Scholar
• Chung DC, McCague S, Yu Z-F, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies: multi-luminance mobility test. Clin Exp Ophthalmol. 2018;46(3):247–259.
   PubMed Web of Science ®Google Scholar
• Cideciyan AV, Jacobson SG, Drack AV, et al. Effect of an intravitreal antisense oligonucleotide on vision in Leber congenital amaurosis due to a photoreceptor cilium defect. Nat Med. 2019;25(2):225–228. doi:10.1038/s41591-018-0295-0
   PubMed Web of Science ®Google Scholar
• Black A, Lovie‐Kitchin JE, Woods RL, Arnold N, Byrnes J, Murrish J. Mobility performance with retinitis pigmentosa. Clin Exp Optom. 1997;80(1):1–12. doi:10.1111/j.1444-0938.1997.tb04841.x
   Google Scholar
• Jacobson SG, Cideciyan AV, Peshenko IV, et al. Determining consequences of retinal membrane guanylyl cyclase (RetGC1) deficiency in human leber congenital amaurosis en route to therapy: residual cone-photoreceptor vision correlates with biochemical properties of the mutants. Hum Mol Genet. 2013;22(1):168–183. doi:10.1093/hmg/dds421
   PubMed Web of Science ®Google Scholar
• Chung DC, McCague S, Yu ZF, et al. Novel mobility test to assess functional vision in patients with inherited retinal dystrophies. Clin Exp Ophthalmol. 2018;46(3):247–259. doi:10.1111/ceo.13022
   PubMed Web of Science ®Google Scholar
• Warren WH, Kay BA, Zosh WD, Duchon AP, Sahuc S. Optic flow is used to control human walking. Nat Neurosci. 2001;4(2):213–216. doi:10.1038/84054
   PubMed Web of Science ®Google Scholar
• Bowers AR, Ananyev E, Mandel AJ, Goldstein RB, Peli E. Driving with hemianopia: IV. Head scanning and detection at intersections in a simulator. Invest Ophthalmol Vis Sci. 2014;55(3):1540–1548. doi:10.1167/iovs.13-12748
   PubMed Web of Science ®Google Scholar
• Apfelbaum H, Pelah A, Peli E. Heading assessment by “tunnel vision” patients and control subjects standing or walking in a virtual reality environment. ACM Trans Appl Percept. 2007;4(1):8. doi:10.1145/1227134.1227142
   Web of Science ®Google Scholar
• Peli E, Apfelbaum H, Berson EL, Goldstein RB. The risk of pedestrian collisions with peripheral visual field loss. J Vis. 2016;16(15):5. doi:10.1167/16.15.5
   Web of Science ®Google Scholar
• Jones PR, Somoskeoy T, Chow-Wing-Bom H, Crabb DP. Seeing other perspectives: evaluating the use of virtual and augmented reality to simulate visual impairments (OpenVisSim). NPJ Digit Med. 2020;3(1):32. doi:10.1038/s41746-020-0242-6
   PubMed Web of Science ®Google Scholar
• Lam AKN, To E, Weinreb RN, et al. Use of virtual reality simulation to identify vision-related disability in patients with glaucoma. JAMA Ophthalmol. 2020;138(5):490–498. doi:10.1001/jamaophthalmol.2020.0392
   Web of Science ®Google Scholar
• Jacobson S, Voigt W, Parel J-M, et al. Automated light- and dark-adapted perimetry for evaluating retinitis pigmentosa. Ophthalmology. 1986;93(12):1604–1611. doi:10.1016/S0161-6420(86)33522-X
   PubMed Web of Science ®Google Scholar
• Aleman TS, Han G, Serrano LW, et al. Natural history of the central structural abnormalities in choroideremia: a prospective cross-sectional study. Ophthalmology. 2017;124(3):359–373. doi:10.1016/j.ophtha.2016.10.022
   PubMed Web of Science ®Google Scholar
• Roman AJ, Schwartz SB, Aleman TS, et al. Quantifying rod photoreceptor-mediated vision in retinal degenerations: dark-adapted thresholds as outcome measures. Exp Eye Res. 2005;80(2):259–272. doi:10.1016/j.exer.2004.09.008
   PubMed Web of Science ®Google Scholar
• Roman AJ, Cideciyan AV, Aleman TS, Jacobson SG. Full-field stimulus testing (FST) to quantify visual perception in severely blind candidates for treatment trials. Physiol Meas. 2007;28(8):N51–56. doi:10.1088/0967-3334/28/8/N02
   PubMed Web of Science ®Google Scholar
• Aleman TS, Uyhazi KE, Serrano LW, et al. RDH12 mutations cause a severe retinal degeneration with relatively spared rod function. Invest Ophthalmol Vis Sci. 2018;59(12):5225–5236. doi:10.1167/iovs.18-24708
   PubMed Web of Science ®Google Scholar
• Uyhazi K, Aravand P, Bell B, et al. Treatment potential for LCA5-associated leber congenital amaurosis. Invest Ophthalmol Vis Sci. 2020;61(5):30. doi:10.1167/iovs.61.5.30
   Web of Science ®Google Scholar
• Kolarik AJ, Cirstea S, Pardhan S, Moore BC. A summary of research investigating echolocation abilities of blind and sighted humans. Hear Res. 2014;310:60–68. doi:10.1016/j.heares.2014.01.010
   PubMed Web of Science ®Google Scholar
• Mees L, Upadhyaya S, Kumar P, et al. Validation of a head-mounted virtual reality visual field screening device. J Glaucoma. 2020;29(2):86–91. doi:10.1097/IJG.0000000000001415
   PubMed Web of Science ®Google Scholar
• Walkey HC, Barbur JL. Guest editorial: shedding new light on the twilight zone. Ophthalmic Physiol Opt. 2006;26(3):223–224. doi:10.1111/j.1475-1313.2006.00420.x
   Web of Science ®Google Scholar
• Walkey HC, Barbur JL, Harlow JA, Hurden A, Moorhead IR, Taylor JA. Effective contrast of colored stimuli in the mesopic range: a metric for perceived contrast based on achromatic luminance contrast. J Opt Soc Am A Opt Image Sci Vis. 2005;22(1):17–28. doi:10.1364/JOSAA.22.000017
   Web of Science ®Google Scholar
• Walkey HC, Harlow JA, Barbur JL. Characterising mesopic spectral sensitivity from reaction times. Vision Res. 2006;46(25):4232–4243. doi:10.1016/j.visres.2006.08.002
   PubMed Web of Science ®Google Scholar
• Walkey HC, Harlow JA, Barbur JL. Changes in reaction time and search time with background luminance in the mesopic range. Ophthalmic Physiol Opt. 2006;26(3):288–299. doi:10.1111/j.1475-1313.2006.00412.x
   Web of Science ®Google Scholar
• Zele AJ, Cao D. Vision under mesopic and scotopic illumination. Front Psychol. 2014;5:1594. doi:10.3389/fpsyg.2014.01594
   Web of Science ®Google Scholar
• Zele AJ, Maynard ML, Feigl B. Rod and cone pathway signaling and interaction under mesopic illumination. J Vis. 2013;13(1):1. doi:10.1167/13.1.21
   Web of Science ®Google Scholar
• Zele AJ, Maynard ML, Joyce DS, Cao D. Effect of rod-cone interactions on mesopic visual performance mediated by chromatic and luminance pathways. J Opt Soc Am A Opt Image Sci Vis. 2014;31(4):A7–A14. doi:10.1364/JOSAA.31.0000A7
   Web of Science ®Google Scholar
• Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. Development of the 25-item national eye institute Visual Function Questionnaire (VFQ-25). Arch Ophthalmol. 2001;119(7):1050–1058. doi:10.1001/archopht.119.7.1050
   PubMed Web of Science ®Google Scholar
• Dougherty BE, Bullimore MA. Comparison of scoring approaches for the NEI VFQ-25 in low vision. Optom Vis Sci. 2010;87(8):543–548. doi:10.1097/OPX.0b013e3181e61bd8
   Web of Science ®Google Scholar
• Massof RW. An interval-scaled scoring algorithm for visual function questionnaires. Optom Vis Sci. 2007;84(8):E690–705. doi:10.1097/OPX.0b013e31812f5f35
   Web of Science ®Google Scholar
• Massof RW. The measurement of vision disability. Optom Vis Sci. 2002;79(8):516–552. doi:10.1097/00006324-200208000-00015
   PubMed Web of Science ®Google Scholar
• Massof RW, Ahmadian L. What do different visual function questionnaires measure? Ophthalmic Epidemiol. 2007;14(4):198–204. doi:10.1080/09286580701487883
   Web of Science ®Google Scholar
• Massof RW, Hsu CT, Baker FH, et al. Visual disability variables. II: the difficulty of tasks for a sample of low-vision patients. Arch Phys Med Rehabil. 2005;86(5):954–967. doi:10.1016/j.apmr.2004.09.017
   Web of Science ®Google Scholar
• Massof RW, Hsu CT, Baker FH, et al. Visual disability variables. I: the importance and difficulty of activity goals for a sample of low-vision patients. Arch Phys Med Rehabil. 2005;86(5):946–953. doi:10.1016/j.apmr.2004.09.016
   PubMed Web of Science ®Google Scholar
• Massof RW, Rubin GS. Visual function assessment questionnaires. Surv Ophthalmol. 2001;45(6):531–548. doi:10.1016/S0039-6257(01)00194-1
   PubMed Web of Science ®Google Scholar
• Jeter PE, Rozanski C, Massof R, Adeyemo O, Dagnelie G. The PSG. Development of the Ultra-Low Vision Visual Functioning Questionnaire (ULV-VFQ). Transl Vis Sci Technol. 2017;6(3):11. doi:10.1167/tvst.6.3.11
   Web of Science ®Google Scholar
• Adeyemo O, Jeter PE, Rozanski C, et al. Living with ultra-low vision: an inventory of self-reported visually guided activities by individuals with profound visual impairment. Transl Vis Sci Technol. 2017;6(3):10. doi:10.1167/tvst.6.3.10
   Web of Science ®Google Scholar